HOXB13 G84E Mutation Associated with Risk of Prostate Cancer
the Cancer Therapy Advisor take:
A rare non-conservative substitution (G84E) in the HOXB13 gene was found to be associated with an increased risk for prostate cancer and other malignancies in male patients, according to a study published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants included 9,012 male patients in the Mayo Clinic Biobank (MCB). DNA samples were genotyped to calculate the frequency of the G84E variant and its relationship with malignancies and patients completed questionnaires regarding medical history and family history of cancer.
Out of the 9,012 males, 49 were carriers of the G84E mutation (0.5%) and 31% (n = 2,595) of patients were diagnosed with cancer (51.1% of which were G84E carriers and 30.6% were non-carriers (P=0.004).
The G84E mutation was most frequently found in males with prostate cancer compared to males without cancer (P0.0001). The authors observed that G84E was more common in patients with bladder cancer and leukemia (P=0.06 and P=0.01, respectively). Male patients who were G84E mutation carriers were more prone to having a family history of prostate cancer in a first degree relative (36.2%) compared with non-carriers (16.0%, P=0.0003).
The study suggests future research focus on understanding the role of the HOXB13 G84E mutation in malignancies and its novel association with leukemia and bladder cancer.
Rare non-conservative substitution in HOXB13 gene found to be associated with increased risk for prostate cancer and other malignancies.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC